Theravance Biopharma says hypotension drug failed to meet primary goal
April 4 (Reuters) - Theravance Biopharma Inc TBPH.O said on Monday its experimental drug to treat a form of hypotension failed to meet its primary goal for the overall population of patients for which it was being tested. (Reporting by Leroy Leo in Bengaluru; Editing by Maju Samuel) ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))
Recent news on Theravance Biopharma
See all newsIreland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth
Ireland's Theravance Biopharma Q4 revenue misses expectations
Corrected: BRIEF-Theravance Biopharma Q4 Operating Income USD 20.012 Million
U.S. STOCKS ON THE MOVE-Versant Media Group, Lithium miners, Expedia Group
U.S. STOCKS ON THE MOVE-Expedia Group, Blue Owl Capital, Enphase Energy